Literature DB >> 26442957

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Frederick S Barrett1, Matthew W Johnson2, Roland R Griffiths3.   

Abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants (n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a "complete mystical experience" that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.
© The Author(s) 2015.

Entities:  

Keywords:  Psilocybin; entheogen; factor analysis; hallucinogens; mystical experience; psychedelic; psychometrics; spiritual; structural equation modeling

Mesh:

Substances:

Year:  2015        PMID: 26442957      PMCID: PMC5203697          DOI: 10.1177/0269881115609019

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  9 in total

1.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

2.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

3.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

4.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

5.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

6.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.

Authors:  Katherine A Maclean; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Sci Study Relig       Date:  2012-12

8.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Authors:  Rr Griffiths; Wa Richards; Mw Johnson; Ud McCann; R Jesse
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

9.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

  9 in total
  85 in total

1.  Psychedelics and connectedness.

Authors:  R L Carhart-Harris; D Erritzoe; E Haijen; M Kaelen; R Watts
Journal:  Psychopharmacology (Berl)       Date:  2017-08-10       Impact factor: 4.530

2.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

3.  High dose psilocybin is associated with positive subjective effects in healthy volunteers.

Authors:  Christopher R Nicholas; Kelsey M Henriquez; Michele C Gassman; Karen M Cooper; Daniel Muller; Scott Hetzel; Randall T Brown; Nicholas V Cozzi; Chantelle Thomas; Paul R Hutson
Journal:  J Psychopharmacol       Date:  2018-06-27       Impact factor: 4.153

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 5.  Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.

Authors:  Sam G Moreton; Luke Szalla; Rachel E Menzies; Andrew F Arena
Journal:  Psychopharmacology (Berl)       Date:  2019-11-29       Impact factor: 4.530

6.  Psilocybin Therapeutic Research: The Present and Future Paradigm.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-03-02       Impact factor: 4.345

7.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

8.  Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.

Authors:  Alan K Davis; Frederick S Barrett; Roland R Griffiths
Journal:  J Contextual Behav Sci       Date:  2019-11-16

9.  Long-term follow-up of psilocybin-facilitated smoking cessation.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Roland R Griffiths
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-21       Impact factor: 3.829

10.  Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Authors:  Theresa M Carbonaro; Matthew W Johnson; Ethan Hurwitz; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2017-11-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.